Financhill
Buy
67

ELAN Quote, Financials, Valuation and Earnings

Last price:
$11.98
Seasonality move :
3.26%
Day range:
$11.92 - $12.28
52-week range:
$8.02 - $18.80
Dividend yield:
0%
P/E ratio:
16.16x
P/S ratio:
1.34x
P/B ratio:
0.94x
Volume:
8.5M
Avg. volume:
6.5M
1-year change:
-30.47%
Market cap:
$5.9B
Revenue:
$4.4B
EPS (TTM):
$0.74

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ELAN
Elanco Animal Health
$1.1B $0.13 0.15% 407.4% $14.18
AMLX
Amylyx Pharmaceuticals
-- -$0.52 -100% -52.34% $10.80
FULC
Fulcrum Therapeutics
-- -$0.29 -100% -24.42% $5.33
LLY
Eli Lilly and
$15.4B $6.12 26.74% 68.13% $978.82
PFE
Pfizer
$17.1B $0.88 1.01% 5555.3% $29.25
ZTS
Zoetis
$2.4B $1.66 1.9% 17.21% $194.12
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ELAN
Elanco Animal Health
$11.96 $14.18 $5.9B 16.16x $0.00 0% 1.34x
AMLX
Amylyx Pharmaceuticals
$4.61 $10.80 $410.9M 21.03x $0.00 0% 3.83x
FULC
Fulcrum Therapeutics
$5.37 $5.33 $289.9M -- $0.00 0% --
LLY
Eli Lilly and
$734.57 $978.82 $659.4B 59.77x $1.50 0.74% 13.54x
PFE
Pfizer
$22.28 $29.25 $126.7B 16.14x $0.43 7.63% 2.03x
ZTS
Zoetis
$159.27 $194.12 $70.9B 28.59x $0.50 1.17% 7.76x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ELAN
Elanco Animal Health
40.89% 2.131 84.31% 1.22x
AMLX
Amylyx Pharmaceuticals
-- -0.377 -- 6.23x
FULC
Fulcrum Therapeutics
-- 0.339 -- 21.84x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
PFE
Pfizer
40.42% 0.423 42.46% 0.88x
ZTS
Zoetis
58.56% 0.874 9.26% 0.91x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ELAN
Elanco Animal Health
$684M $121M 3.36% 6.02% 8.38% -$69M
AMLX
Amylyx Pharmaceuticals
-- -$37.8M -109.32% -109.32% 6113.38% -$39.8M
FULC
Fulcrum Therapeutics
-- -$20.4M -8.07% -8.07% 65.62% -$15.3M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B
ZTS
Zoetis
$1.6B $846M 21.88% 51.03% 38.92% $438M

Elanco Animal Health vs. Competitors

  • Which has Higher Returns ELAN or AMLX?

    Amylyx Pharmaceuticals has a net margin of 5.62% compared to Elanco Animal Health's net margin of -17476.92%. Elanco Animal Health's return on equity of 6.02% beat Amylyx Pharmaceuticals's return on equity of -109.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
  • What do Analysts Say About ELAN or AMLX?

    Elanco Animal Health has a consensus price target of $14.18, signalling upside risk potential of 18.58%. On the other hand Amylyx Pharmaceuticals has an analysts' consensus of $10.80 which suggests that it could grow by 134.27%. Given that Amylyx Pharmaceuticals has higher upside potential than Elanco Animal Health, analysts believe Amylyx Pharmaceuticals is more attractive than Elanco Animal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELAN
    Elanco Animal Health
    6 7 0
    AMLX
    Amylyx Pharmaceuticals
    4 1 0
  • Is ELAN or AMLX More Risky?

    Elanco Animal Health has a beta of 1.494, which suggesting that the stock is 49.375% more volatile than S&P 500. In comparison Amylyx Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ELAN or AMLX?

    Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amylyx Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Amylyx Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELAN or AMLX?

    Elanco Animal Health quarterly revenues are $1.2B, which are larger than Amylyx Pharmaceuticals quarterly revenues of -$665K. Elanco Animal Health's net income of $67M is higher than Amylyx Pharmaceuticals's net income of -$35.9M. Notably, Elanco Animal Health's price-to-earnings ratio is 16.16x while Amylyx Pharmaceuticals's PE ratio is 21.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.34x versus 3.83x for Amylyx Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELAN
    Elanco Animal Health
    1.34x 16.16x $1.2B $67M
    AMLX
    Amylyx Pharmaceuticals
    3.83x 21.03x -$665K -$35.9M
  • Which has Higher Returns ELAN or FULC?

    Fulcrum Therapeutics has a net margin of 5.62% compared to Elanco Animal Health's net margin of 69.26%. Elanco Animal Health's return on equity of 6.02% beat Fulcrum Therapeutics's return on equity of -8.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
    FULC
    Fulcrum Therapeutics
    -- -$0.28 $273.8M
  • What do Analysts Say About ELAN or FULC?

    Elanco Animal Health has a consensus price target of $14.18, signalling upside risk potential of 18.58%. On the other hand Fulcrum Therapeutics has an analysts' consensus of $5.33 which suggests that it could fall by -0.68%. Given that Elanco Animal Health has higher upside potential than Fulcrum Therapeutics, analysts believe Elanco Animal Health is more attractive than Fulcrum Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELAN
    Elanco Animal Health
    6 7 0
    FULC
    Fulcrum Therapeutics
    1 4 0
  • Is ELAN or FULC More Risky?

    Elanco Animal Health has a beta of 1.494, which suggesting that the stock is 49.375% more volatile than S&P 500. In comparison Fulcrum Therapeutics has a beta of 2.293, suggesting its more volatile than the S&P 500 by 129.324%.

  • Which is a Better Dividend Stock ELAN or FULC?

    Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Fulcrum Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ELAN or FULC?

    Elanco Animal Health quarterly revenues are $1.2B, which are larger than Fulcrum Therapeutics quarterly revenues of $80M. Elanco Animal Health's net income of $67M is higher than Fulcrum Therapeutics's net income of -$17.7M. Notably, Elanco Animal Health's price-to-earnings ratio is 16.16x while Fulcrum Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.34x versus -- for Fulcrum Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELAN
    Elanco Animal Health
    1.34x 16.16x $1.2B $67M
    FULC
    Fulcrum Therapeutics
    -- -- $80M -$17.7M
  • Which has Higher Returns ELAN or LLY?

    Eli Lilly and has a net margin of 5.62% compared to Elanco Animal Health's net margin of 21.68%. Elanco Animal Health's return on equity of 6.02% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About ELAN or LLY?

    Elanco Animal Health has a consensus price target of $14.18, signalling upside risk potential of 18.58%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Eli Lilly and has higher upside potential than Elanco Animal Health, analysts believe Eli Lilly and is more attractive than Elanco Animal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELAN
    Elanco Animal Health
    6 7 0
    LLY
    Eli Lilly and
    15 3 1
  • Is ELAN or LLY More Risky?

    Elanco Animal Health has a beta of 1.494, which suggesting that the stock is 49.375% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock ELAN or LLY?

    Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Elanco Animal Health pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ELAN or LLY?

    Elanco Animal Health quarterly revenues are $1.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Elanco Animal Health's net income of $67M is lower than Eli Lilly and's net income of $2.8B. Notably, Elanco Animal Health's price-to-earnings ratio is 16.16x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.34x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELAN
    Elanco Animal Health
    1.34x 16.16x $1.2B $67M
    LLY
    Eli Lilly and
    13.54x 59.77x $12.7B $2.8B
  • Which has Higher Returns ELAN or PFE?

    Pfizer has a net margin of 5.62% compared to Elanco Animal Health's net margin of 21.63%. Elanco Animal Health's return on equity of 6.02% beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About ELAN or PFE?

    Elanco Animal Health has a consensus price target of $14.18, signalling upside risk potential of 18.58%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Pfizer has higher upside potential than Elanco Animal Health, analysts believe Pfizer is more attractive than Elanco Animal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELAN
    Elanco Animal Health
    6 7 0
    PFE
    Pfizer
    6 15 1
  • Is ELAN or PFE More Risky?

    Elanco Animal Health has a beta of 1.494, which suggesting that the stock is 49.375% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock ELAN or PFE?

    Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Elanco Animal Health pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios ELAN or PFE?

    Elanco Animal Health quarterly revenues are $1.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Elanco Animal Health's net income of $67M is lower than Pfizer's net income of $3B. Notably, Elanco Animal Health's price-to-earnings ratio is 16.16x while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.34x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELAN
    Elanco Animal Health
    1.34x 16.16x $1.2B $67M
    PFE
    Pfizer
    2.03x 16.14x $13.7B $3B
  • Which has Higher Returns ELAN or ZTS?

    Zoetis has a net margin of 5.62% compared to Elanco Animal Health's net margin of 28.42%. Elanco Animal Health's return on equity of 6.02% beat Zoetis's return on equity of 51.03%.

    Company Gross Margin Earnings Per Share Invested Capital
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
    ZTS
    Zoetis
    71.98% $1.41 $11.2B
  • What do Analysts Say About ELAN or ZTS?

    Elanco Animal Health has a consensus price target of $14.18, signalling upside risk potential of 18.58%. On the other hand Zoetis has an analysts' consensus of $194.12 which suggests that it could grow by 21.88%. Given that Zoetis has higher upside potential than Elanco Animal Health, analysts believe Zoetis is more attractive than Elanco Animal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    ELAN
    Elanco Animal Health
    6 7 0
    ZTS
    Zoetis
    10 5 0
  • Is ELAN or ZTS More Risky?

    Elanco Animal Health has a beta of 1.494, which suggesting that the stock is 49.375% more volatile than S&P 500. In comparison Zoetis has a beta of 0.942, suggesting its less volatile than the S&P 500 by 5.835%.

  • Which is a Better Dividend Stock ELAN or ZTS?

    Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.17% to investors and pays a quarterly dividend of $0.50 per share. Elanco Animal Health pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ELAN or ZTS?

    Elanco Animal Health quarterly revenues are $1.2B, which are smaller than Zoetis quarterly revenues of $2.2B. Elanco Animal Health's net income of $67M is lower than Zoetis's net income of $631M. Notably, Elanco Animal Health's price-to-earnings ratio is 16.16x while Zoetis's PE ratio is 28.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.34x versus 7.76x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ELAN
    Elanco Animal Health
    1.34x 16.16x $1.2B $67M
    ZTS
    Zoetis
    7.76x 28.59x $2.2B $631M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock